NPM–RAR, not the RAR–NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation

References

• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505–2515.
   PubMed Web of Science ®Google Scholar
• Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167–3215.
   PubMed Web of Science ®Google Scholar
• He LZ, Tribioli C, Rivi R, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci USA 1997;94:5302–5307.
   PubMed Web of Science ®Google Scholar
• Brown D, Kogan S, Lagasse E, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:2551–2556.
   PubMed Web of Science ®Google Scholar
• He LZ, Bhaumik M, Tribioli C, et al. Two critical hits for promyelocytic leukemia. Mol Cell 2000;6:1131–1141.
   PubMed Web of Science ®Google Scholar
• Alcalay M, Zangrilli D, Fagioli M, et al. Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992;89:4840–4844.
   PubMed Web of Science ®Google Scholar
• Borrow J, Goddard AD, Gibbons B, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARA and RARA-PML fusion transcripts. Br J Haematol 1992;82:529–540.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Biondi A, Mozziconacci MJ, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d’Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action “Molecular Cytogenetic Diagnosis in Haematological Malignancies”. Blood 2000;96:1297–1308.
   PubMed Web of Science ®Google Scholar
• Li YP, Andersen J, Zelent A, et al. RAR alpha1/RAR alpha2-PML mRNA expression in acute promyelocytic leukemia cells: a molecular and laboratory-clinical correlative study. Blood 1997;90:306–312.
   PubMed Web of Science ®Google Scholar
• Walz C, Grimwade D, Saussele S, et al. Atypical mRNA fusions in PML-RARA positive, RARA-PML negative acute promyelocytic leukemia. Genes Chromosomes Cancer 2010;49:471–479.
   PubMed Web of Science ®Google Scholar
• Pollock JL, Westervelt P, Kurichety AK, et al. A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia. Proc Natl Acad Sci USA 1999;96: 15103–15108.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ries RE, Armstrong JR, et al. Expression of a bcr-1 isoform of RARalpha-PML does not affect the penetrance of acute promyelocytic leukemia or the acquisition of an interstitial deletion on mouse chromosome 2. Blood 2007;109:1237–1240.
   PubMed Web of Science ®Google Scholar
• Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia 2002;16:1927–1932.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993;12:1161–1167.
   PubMed Web of Science ®Google Scholar
• Redner RL, Rush EA, Faas S, et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882–886.
   PubMed Web of Science ®Google Scholar
• Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet 1997;17:109–113.
   PubMed Web of Science ®Google Scholar
• Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999;8:1741–1749.
   PubMed Web of Science ®Google Scholar
• Catalano A, Dawson MA, Somana K, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007;110:4073–4076.
   PubMed Web of Science ®Google Scholar
• Kondo T, Mori A, Darmanin S, et al. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica 2008;93:1414–1416.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Tsuzuki S, Tsuzuki M, et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood 2010;116:4274–4283.
   PubMed Web of Science ®Google Scholar
• Redner RL, Corey SJ, Rush EA. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia 1997;11:1014–1016.
   PubMed Web of Science ®Google Scholar
• Corey SJ, Locker J, Oliveri DR, et al. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features. Leukemia 1994;8:1350–1353.
   PubMed Web of Science ®Google Scholar
• Du C, Redner RL, Cooke MP, et al. Overexpression of wild- type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood 1999; 94:793–802.
   PubMed Web of Science ®Google Scholar
• Kamel-Reid S, Zhang T, Wells RA. Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. Oncogene 2003;22:6424–6435.
   PubMed Web of Science ®Google Scholar
• Rego EM, Ruggero D, Tribioli C, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 2006;25:1974–1979.
   PubMed Web of Science ®Google Scholar
• Cheng GX, Zhu XH, Men XQ, et al. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha. Proc Natl Acad Sci USA 1999;96:6318–6323.
   PubMed Web of Science ®Google Scholar
• Redner RL, Chen JD, Rush EA, et al. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties. Blood 2000;95:2683–2690.
   PubMed Web of Science ®Google Scholar
• Grignani F, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993;74:423–431.
   PubMed Web of Science ®Google Scholar
• Ruthardt M, Testa U, Nervi C, et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling. Mol Cell Biol 1997;17:4859–4869.
   PubMed Web of Science ®Google Scholar
• Puccetti E, Obradovic D, Beissert T, et al. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002;62: 7050–7058.
   PubMed Web of Science ®Google Scholar
• Guidez F, Parks S, Wong H, et al. RARalpha-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proc Natl Acad Sci USA 2007;104:18694–18699.
   PubMed Web of Science ®Google Scholar
• Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011;30:2595–2609.
   PubMed Web of Science ®Google Scholar
• Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103: 127–140.
   PubMed Web of Science ®Google Scholar
• Lin CY, Liang YC, Yung BY. Nucleophosmin/B23 regulates transcriptional activation of E2F1 via modulating the promoter binding of NF-kappaB, E2F1 and pRB. Cell Signal 2006;18:2041–2048.
   PubMed Web of Science ®Google Scholar
• Liu QR, Chan PK. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein. Eur J Biochem 1991;200:715–721.
   PubMedGoogle Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
   PubMed Web of Science ®Google Scholar